RESUMEN
This year is the 50th anniversary of the publication of a paper by Milan Hasek, in which he showed the phenomenon of immunological tolerance by the selective failure of chimaeric chick-embryo parabionts to produce antibodies against the red blood cells of each other. The discovery of tolerance was credited by the Nobel prize, but excluded Hasek, because he misinterpreted his original experimental results. Hasek exuded an impressive personality and a much admired joie de vivre. With the benefit of hindsight, this article assesses the background of the period and the circumstances that led to this important discovery. I discuss Hasek's experimental ingenuity, the influence of the Lysenkoist genetic doctrine, Hasek's acceptance of the immunological theory to explain his work and his role in establishing a successful institute at the Czechoslovak Academy of Sciences.
Asunto(s)
Alergia e Inmunología/historia , Tolerancia Inmunológica , Animales , Checoslovaquia , Genética/historia , Historia del Siglo XX , Parabiosis/historiaRESUMEN
Abs have been shown to be protective in passive immunotherapy of tuberculous infection using mouse experimental models. In this study, we report on the properties of a novel human IgA1, constructed using a single-chain variable fragment clone (2E9), selected from an Ab phage library. The purified Ab monomer revealed high binding affinities for the mycobacterial α-crystallin Ag and for the human FcαRI (CD89) IgA receptor. Intranasal inoculations with 2E9IgA1 and recombinant mouse IFN-γ significantly inhibited pulmonary H37Rv infection in mice transgenic for human CD89 but not in CD89-negative littermate controls, suggesting that binding to CD89 was necessary for the IgA-imparted passive protection. 2E9IgA1 added to human whole-blood or monocyte cultures inhibited luciferase-tagged H37Rv infection although not for all tested blood donors. Inhibition by 2E9IgA1 was synergistic with human rIFN-γ in cultures of purified human monocytes but not in whole-blood cultures. The demonstration of the mandatory role of FcαRI (CD89) for human IgA-mediated protection is important for understanding of the mechanisms involved and also for translation of this approach toward development of passive immunotherapy of tuberculosis.
Asunto(s)
Anticuerpos Monoclonales/uso terapéutico , Inmunoglobulina A/uso terapéutico , Mycobacterium tuberculosis/inmunología , Tuberculosis Pulmonar/inmunología , Tuberculosis Pulmonar/terapia , Animales , Anticuerpos Monoclonales/administración & dosificación , Anticuerpos Monoclonales/metabolismo , Antígenos CD/genética , Antígenos CD/metabolismo , Antígenos CD/uso terapéutico , Sitios de Unión de Anticuerpos/inmunología , Células CHO , Cricetinae , Cricetulus , Humanos , Inmunización Pasiva/métodos , Inmunoglobulina A/administración & dosificación , Inmunoglobulina A/metabolismo , Ratones , Ratones Transgénicos , Mycobacterium bovis/inmunología , Receptores Fc/genética , Receptores Fc/metabolismo , Receptores Fc/uso terapéutico , alfa-Cristalinas/inmunologíaRESUMEN
Confrontation between invading microbial pathogens and host defense systems involves intricate cellular and molecular interactions. Here we discuss the virulence factors as trumps, overriding the contest in favor of the tubercle bacillus (Mycobacterium tuberculosis). It evolved a number of molecular constituents, which can interfere with antigen presentation and Toll receptor function, thus impairing immune defenses. It also evolved stress responses, which can drive its cell cycle into a non-replicating, low metabolic mode. Although the low counts of latent bacilli prevent their direct detection, we contend that they retain a capacity to survive for long periods in foamy macrophages and within the necrotic parts of lung granulomas. We attributed significance to drainage of M. tuberculosis by the alveolar fluid: while out-flow is responsible for the clearance, the reverse-flow has an important capacity to re-infect the lungs and to transmit the infection to new recipients. We consider the cycling between replicating and latent organisms to be a continuous process, which is a departure from the concept of long-lived dormant organisms, with a capacity to resuscitate. These aspects impinge also on the actions of isoniazid (INH) chemotherapy and on the topography of human lung lesions. Eventually, fibrosis of the connective tissue of the lungs is known to encapsulate lung lesions, thus limiting the impact of both outward and reverse drainage. In conclusion, the novelty of our views on M. tuberculosis-host interactions rests in the dynamic perception of M. tuberculosis latency and its evolutionary importance for the pathogenesis of tuberculosis.
Asunto(s)
Interacciones Huésped-Patógeno/fisiología , Mycobacterium tuberculosis/patogenicidad , Tuberculosis/microbiología , Aerosoles , Presentación de Antígeno , Antígenos Bacterianos/inmunología , Antituberculosos/administración & dosificación , Antituberculosos/farmacocinética , Antituberculosos/uso terapéutico , Proteínas Bacterianas/fisiología , Citocinas/fisiología , Fibrosis , Humanos , Evasión Inmune/inmunología , Isoniazida/administración & dosificación , Isoniazida/farmacocinética , Isoniazida/uso terapéutico , Tuberculosis Latente/epidemiología , Tuberculosis Latente/inmunología , Tuberculosis Latente/microbiología , Macrófagos/microbiología , Modelos Biológicos , Mycobacterium tuberculosis/efectos de los fármacos , Mycobacterium tuberculosis/crecimiento & desarrollo , Mycobacterium tuberculosis/inmunología , Alveolos Pulmonares/microbiología , Alveolos Pulmonares/fisiopatología , Distribución Tisular , Tuberculoma/microbiología , Tuberculosis/tratamiento farmacológico , Tuberculosis/inmunología , Tuberculosis/patología , Tuberculosis/transmisión , Tuberculosis Pulmonar/tratamiento farmacológico , Tuberculosis Pulmonar/microbiología , Tuberculosis Pulmonar/patología , Factor de Necrosis Tumoral alfa/fisiología , Virulencia/fisiologíaRESUMEN
Current search for a new effective vaccine against tuberculosis involves selected antigens, vectors and adjuvants. These are being evaluated usually by their booster inoculation following priming with Bacillus Calmette-Guerin. The purpose of this article is to point out, that despite being attenuated of virulence, priming with BCG may still involve immune mechanisms, which are not favourable for protection against active disease. It is postulated, that the responsible 'decoy' constituents selected during the evolution of pathogenic tubercle bacilli may be involved in the evasion from bactericidal host resistance and stimulate immune responses of a cytokine phenotype, which lead to the transition from latent closed granulomas to reactivation with infectious lung cavities. The decoy mechanisms appear as favourable for most infected subjects but leading in a minority of cases to pathology which can effectively transmit the infection. It is proposed that construction and development of new vaccine candidates could benefit from avoiding decoy-type immune mechanisms.
Asunto(s)
Mycobacterium tuberculosis/inmunología , Vacunas contra la Tuberculosis/farmacología , Tuberculosis/prevención & control , Vacunación/métodos , Animales , Humanos , Tuberculosis/microbiologíaAsunto(s)
Tamizaje Masivo/métodos , Tuberculosis Pulmonar/diagnóstico , Control de Enfermedades Transmisibles/métodos , Diagnóstico Precoz , Ensayos Analíticos de Alto Rendimiento/métodos , Humanos , Londres , Medición de Riesgo , Tuberculosis Pulmonar/tratamiento farmacológico , Tuberculosis Pulmonar/prevención & controlRESUMEN
T cells recognizing epitopes on the surface of mycobacteria-infected macrophages can impart protection, but with associated risk for reactivation to lung pathology. We aimed to identify antibodies specific to such epitopes, which carry potentials for development toward novel therapeutic constructs. Since epitopes presented in the context of major histocompatibility complex alleles are rarely recognized by naturally produced antibodies, we used a phage display library for the identification of monoclonal human single domain antibody producing clones. The selected 2C clone displayed T cell receptor-like recognition of an HLA-A*0201 bound 199KLVANNTRL207 peptide from the Ag85B antigen, which is known to be an immunodominant epitope for human T cells. The specificity of the selected domain antibody was demonstrated by solid phase immunoassay and by immunofluorescent surface staining of peptide loaded cells of the T2 cell line. The antibody affinity binding was determined by biolayer interferometry. Our results validated the used technologies as suitable for the generation of antibodies against epitopes on the surface of Mycobacterium tuberculosis infected cells. The potential approaches forward the development of antibody in immunotherapy of tuberculosis have been outlined in the discussion.
Asunto(s)
Aciltransferasas/inmunología , Antígenos Bacterianos/inmunología , Antituberculosos/farmacología , Proteínas Bacterianas/inmunología , Antígenos HLA-A/inmunología , Epítopos Inmunodominantes , Mycobacterium tuberculosis/inmunología , Anticuerpos de Cadena Única/farmacología , Linfocitos T/inmunología , Tuberculosis/prevención & control , Especificidad de Anticuerpos , Antituberculosos/inmunología , Línea Celular Tumoral , Técnicas de Visualización de Superficie Celular , Ensayo de Inmunoadsorción Enzimática , Técnica del Anticuerpo Fluorescente , Humanos , Anticuerpos de Cadena Única/genética , Anticuerpos de Cadena Única/inmunología , Tuberculosis/inmunología , Tuberculosis/microbiologíaRESUMEN
New evidence has been emerging that antibodies can be protective in various experimental models of tuberculosis. Here, we report on protection against multidrug-resistant Mycobacterium tuberculosis (MDR-TB) infection using a combination of the human monoclonal IgA 2E9 antibody against the alpha-crystallin (Acr, HspX) antigen and mouse interferon-gamma in mice transgenic for the human IgA receptor, CD89. The effect of the combined mucosal IgA and IFN-γ; treatment was strongest (50-fold reduction) when therapy was applied at the time of infection, but a statistically significant reduction of lung bacterial load was observed even when the therapy was initiated once the infection had already been established. The protection involving enhanced phagocytosis and then neutrophil mediated killing of infected cells was IgA isotype mediated, because treatment with an IgG version of 2E9 antibody was not effective in human IgG receptor CD64 transgenic mice. The Acr antigen specificity of IgA antibodies for protection in humans has been indicated by their elevated serum levels in latent tuberculosis unlike the lack of IgA antibodies against the virulence-associated MPT64 antigen. Our results represent the first evidence for potential translation of mucosal immunotherapy for the management of MDR-TB.
Asunto(s)
Interferón gamma/uso terapéutico , Pulmón/inmunología , Mycobacterium tuberculosis/fisiología , Neutrófilos/inmunología , Mucosa Respiratoria/inmunología , Tuberculosis/terapia , Animales , Anticuerpos Monoclonales/metabolismo , Antígenos Bacterianos/inmunología , Antígenos CD/genética , Antígenos CD/metabolismo , Carga Bacteriana , Proteínas Bacterianas/inmunología , Resistencia a Múltiples Medicamentos , Humanos , Inmunoglobulina A/metabolismo , Pulmón/microbiología , Ratones , Ratones Transgénicos , Mycobacterium tuberculosis/patogenicidad , Fagocitosis , Receptores Fc/genética , Receptores Fc/metabolismo , Receptores de IgG/genética , Células THP-1 , Células U937 , alfa-Cristalinas/inmunologíaRESUMEN
HIV-associated tuberculosis is escalating ominously in Africa and southeast Asia despite existing control measures. Therefore, new approaches to tuberculosis control need to be explored. We discuss the potential use of passive immunoprophylaxis with antibodies in tuberculosis control. Although the predominant type of active host resistance is T-cell mediated, recent results in mouse experimental models suggest that monoclonal antibodies to certain antigens (eg, Acr or lipoarabinomannan) can impart substantial passive protection against tuberculous infection. These results are corroborated by data from other laboratories on passive vaccination against a number of intracellular microbial pathogens. Further work is needed to develop human (or humanised) antibody reagents, to increase their protective efficacy, and to expand our understanding of the mechanisms of antibody action.
Asunto(s)
Anticuerpos Monoclonales/uso terapéutico , Infecciones por VIH/complicaciones , Inmunización Pasiva/métodos , Tuberculosis/prevención & control , Animales , Anticuerpos Monoclonales/inmunología , Humanos , Ratones , Modelos Inmunológicos , Tuberculosis/etiología , Tuberculosis/inmunologíaRESUMEN
Immunotherapeutic approaches, which have been considered for tuberculosis (TB), include immuno-potentiating or suppressing agents, cytokines, antibodies, DNA vaccines, non-pathogenic mycobacteria and mycobacterial extracts. While most or all of these potential agents showed at least some degree of promise in various experimental models, few progressed to clinical trials, yielding only moderately encouraging, though controversial results. Consequently, further research is required, as the need for an immunological agent, adjunct to chemotherapy, remains strongly justified. Its purpose is to shorten the currently protracted (6-9 months) drug treatment and thus increase compliance rates, which are most disappointing in areas with the highest disease prevalence. Using a mouse model of Mycobacterium tuberculosis (Mtb) infection, we recently reported, that an intranasally given monoclonal IgA antibody significantly reduced the bacterial load in the infected lungs, and that this protective effect of IgA could be further extended by co-inoculation with interferon gamma (IFNgamma). In this review, we describe the main features of IgA and its cellular receptors, the extent and possible mechanisms of passive vaccination with an IgA monoclonal antibody against the alpha-crystallin antigen of Mtb and discuss the potentials of this approach in the wider context of immunotherapy of TB.
Asunto(s)
Inmunización Pasiva/métodos , Inmunoglobulina A/uso terapéutico , Tuberculosis/terapia , Animales , Anticuerpos Monoclonales/uso terapéutico , Humanos , Inmunidad Mucosa , Inmunoglobulina A/inmunología , Interferón gamma/uso terapéutico , Ratones , Receptores Fc/inmunología , Tuberculosis/inmunologíaRESUMEN
The beta-galactoside-binding S-type lectin galectin-3/Mac-2, expressed among several other cell types on activated macrophages, is known to bind IgE, but not other Ig classes. We report in this paper that the single major constituent in a detergent lysate from the J774 mouse macrophage cell line bound to a mouse monoclonal IgA-affinity column. This fraction has been identified by mass spectrometry analysis as galectin-3. Binding of both mouse IgA and IgE to galectin-3 coated plates was inhibited by lactose and asialofetuin. Furthermore, three different monoclonal IgAs bound also to purified recombinant hamster galectin-3 coated plates in a concentration dependent manner. The potential functional significance of IgA binding to galectin-3 within macrophages and possibly other cell types is discussed.
Asunto(s)
Anticuerpos Monoclonales/inmunología , Galectina 3/inmunología , Inmunoglobulina A/inmunología , Macrófagos/inmunología , Animales , Carbohidratos/inmunología , Cromatografía de Afinidad , Ensayo de Inmunoadsorción Enzimática , Galectina 3/aislamiento & purificación , Ligandos , RatonesRESUMEN
The objective of the study was to identify Mycobacterium leprae-specific immunogenic peptides for the development of a skin test reagent. Such a reagent is required for the detection of M. leprae infection and possibly for the diagnosis of patients with active leprosy. For this purpose, we analyzed the in vitro responses of human peripheral blood mononuclear cell (PBMCs) to peptides from the 35 kDa protein of M. leprae. This protein is of interest since it has no homologue within the Mycobacterium tuberculosis complex, although it has a homologue in Mycobacterium avium. The subjects enrolled in the study were paucibacillary (PB) and multibacillary (MB) leprosy patients, healthy contacts, and non-contacts. Seventy-three PB and 124 MB leprosy patients were recruited from four leprosy clinics in Thailand. Fifty-seven healthy contacts were household contacts. Twenty non-leprosy contacts had no family history of or exposure to leprosy. PBMCs from individuals were tested for stimulation with 12 overlapping peptides from the M. leprae 35 kDa protein using the lymphocyte proliferation assay. These peptides were located in four areas containing three to six residues which were distinct for the M. leprae product in comparison to that from M. avium. Four peptides (p60-76, p132-151, p206-224 and p267-286), which were the most permissive from each region and recognized by non-contacts with significantly lower frequencies than other subject groups, were identified. From this preliminary result, we conclude that these four peptides were likely to be M. leprae-specific.
Asunto(s)
Proteínas Bacterianas/inmunología , Epítopos , Antígenos HLA-DR/genética , Lepra/inmunología , Mycobacterium leprae/inmunología , Péptidos/inmunología , Adulto , Proteínas Bacterianas/química , Femenino , Genes MHC Clase II , Antígenos HLA-DR/inmunología , Humanos , Lepra/diagnóstico , Activación de Linfocitos , Masculino , Datos de Secuencia Molecular , Peso Molecular , Mycobacterium avium/inmunología , Péptidos/síntesis química , Péptidos/química , Especificidad de la Especie , TailandiaRESUMEN
Study of the function of epitopes of Mycobacterium tuberculosis antigens contributed significantly toward better understanding of the immunopathogenesis and to efforts for improving infection and disease control. Characterization of genetically permissively presented immunodominant epitopes has implications for the evolution of the host-parasite relationship, development of immunodiagnostic tests, and subunit prophylactic vaccines. Knowledge of the determinants of cross-sensitization, relevant to other pathogenic or environmental mycobacteria and to host constituents has advanced. Epitope-defined IFNγ assay kits became established for the specific detection of infection with tubercle bacilli both in humans and cattle. The CD4 T-cell epitope repertoire was found to be more narrow in patients with active disease than in latently infected subjects. However, differential diagnosis of active TB could not be made reliably merely on the basis of epitope recognition. The mechanisms by which HLA polymorphism can influence the development of multibacillary tuberculosis (TB) need further analysis of epitopes, recognized by Th2 helper cells for B-cell responses. Future vaccine development would benefit from better definition of protective epitopes and from improved construction and formulation of subunits with enhanced immunogenicity. Epitope-defined serology, due to its operational advantages is suitable for active case finding in selected high disease incidence populations, aiming for an early detection of infectious cases and hence for reducing the transmission of infection. The existing knowledge of HLA class I binding epitopes could be the basis for the construction of T-cell receptor-like ligands for immunotherapeutic application. Continued analysis of the functions of mycobacterial epitopes, recognized by T cells and antibodies, remains a fertile avenue in TB research.
RESUMEN
Development of novel diagnostics for tuberculosis has so far been governed by the clinical requirement of improving the detection of patients with paucibacillary forms of the disease. For this aim, serological assays have been evaluated using several antigens, but were found insufficiently sensitive, because antibody production associates with the bacterial load of the disease. Consequently, detection of antibodies against a relatively small number of selected well-defined antigens has a much higher sensitivity for sputum smear-positive pulmonary disease in adult HIV-negative patients. They are the most active in generating and spreading aerosols containing live tubercle bacilli, but their detection is often delayed, thus perpetuating the transmission of the infection and disease in the population. High volume throughput serological screening of clinical suspects with mild clinical symptoms may help to achieve diagnosis earlier, than currently used procedures. Such expanded testing could be done more efficiently in laboratories, than at 'points-of-care' and at a lower cost than other tests. The feasibility of this approach towards reducing the delayed diagnosis of the most infectious cases of pulmonary tuberculosis needs to be ascertained in prospective diagnostic trials, in populations at a high risk. Reducing the transmission of tuberculosis is of key importance for achieving its continued decline and therefore it is proposed, that the aims of serological screening should shift from clinical to public health priorities.
Asunto(s)
Mycobacterium tuberculosis/aislamiento & purificación , Esputo/microbiología , Tuberculosis Pulmonar/diagnóstico , Anticuerpos Antibacterianos/aislamiento & purificación , Diagnóstico Tardío/prevención & control , Farmacorresistencia Bacteriana , Femenino , Humanos , Masculino , Mycobacterium tuberculosis/inmunología , Salud Pública , Reproducibilidad de los Resultados , Pruebas Serológicas , Tuberculosis Pulmonar/microbiologíaAsunto(s)
Congresos como Asunto , Inmunidad , Sociedades Científicas , Linfocitos T/inmunología , Animales , Humanos , Factores de TiempoRESUMEN
We report that a recently developed combined immunotherapy (CIT) has the capacity to prevent a spontaneous relapse of replicating Mycobacterium tuberculosis bacilli in the lungs of BALB/c, C57Bl/6 or C3H/HeJ strains of mice, following 4weeks of non-sterilising treatment with isoniazid and rifampicin. The CIT regimen, represented by recombinant IFNgamma, anti-alpha crystalline monoclonal IgA antibody and IL-4 neutralizing polyclonal antibody, reduced the 8-week relapse of viable bacterial counts in the lungs most significantly, when CIT was inoculated during the 5th week post infection, i.e. during the 3rd week of chemotherapy. Although CIT enhanced lung granuloma area, nitric oxide, cytokine and chemokine levels in lung washings significantly, these could not be directly associated with the beneficial effect of CIT on the degree of relapse in the lungs. These results represent a proof-of-principle, that the described CIT, when combined with chemotherapy, could have potential for future development of a shorter regimen of tuberculosis treatment.